alm2, First, thank you for your apology to Raf, he deserves credit for
standing by this board and letting others present their views.
Second, in the stock world of Biotech strange things are possible. This
company has an amazing game changing drug that is ignored or dismissed
by the powers that be. Nissen is a good example of this. Why?
Third, I maintain that with the right BP acquirer, Vascepa could become
a mega-blockbuster drug in Europe...that would be peak revenues of over
$2 billion a year. Should make a BO worth over $20 for the value of
Europe alone. Does a BP exist that understands the true uses of Vascepa
or its MOA? Has any BP modelled what they could do with Vascepa in
Europe?
Finally, what does JT's BOD think about their situation? Do they believe
(as I do) that the best remedy is a sale of the company to the right BP?
News 
Market Data 
Discover 
